SLC5A2 and type 2 diabetes mellitus: The present study aims to investigate comparative dementia risk with initiators of GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors in people with type 2 diabetes aged ≥ 60 years, using real-world observational data from primary care practice records in the UK.